Tags

Type your tag names separated by a space and hit enter

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.
Pediatrics. 2010 Feb; 125(2):e199-207.Ped

Abstract

OBJECTIVE

The goal was to assess the effectiveness of complete (3-dose) or partial (1- or 2-dose) immunization with pentavalent rotavirus vaccine (RV5) against rotavirus acute gastroenteritis (AGE) in US clinical practice.

METHODS

A case-control evaluation was conducted in February through June 2008 at an emergency department in Houston, Texas. Case patients with rotavirus AGE (N = 90) were identified through testing for rotavirus in fecal specimens obtained from 205 children 15 days through 23 months of age presenting with AGE. Control groups included rotavirus-negative AGE patients (N = 115), concurrently enrolled patients with acute respiratory infection (ARI) (N = 228), and up to 10 age- and zip code-matched children sampled from the Houston-Harris County Immunization Registry (HHCIR) for each case patient >8 months of age. Immunization data were obtained from parent records, health care providers, and/or the HHCIR. Vaccine effectiveness was calculated as 1 minus odds of RV5 vaccination for case patients versus control patients, after adjustment for age at presentation and birth date.

RESULTS

The vaccine effectiveness of a complete RV5 series was 89% (95% confidence interval [CI]: 70%-96%) and 85% (95% CI: 55%-95%) with rotavirus-negative AGE and ARI control patients, respectively. Immunization data were available for 44% of case patients (n = 40) from the HHCIR; the estimated 3-dose vaccine effectiveness with these HHCIR control patients was 82% (95% CI: 19%-96%). A complete RV5 series conferred 100% protection (95% CI: 71%-100%) against severe rotavirus disease requiring hospitalization and 96% protection (95% CI: 72%-99%) against disease requiring intravenous hydration. Vaccine effectiveness of 1 and 2 doses against hospitalization and emergency department visits was 69% (95% CI: 13%-89%) and 81% (95% CI: 13%-96%), respectively, using rotavirus-negative AGE and ARI control groups combined.

CONCLUSIONS

In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE. Partial immunization also conferred substantial protection.

Authors+Show Affiliations

Baylor College of Medicine, Center for Vaccine Awareness and Research, Texas Children's Hospital, 6701 Fannin St, CC1540, Houston, TX 77030, USA. jboom@bcm.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20083525

Citation

Boom, Julie A., et al. "Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States." Pediatrics, vol. 125, no. 2, 2010, pp. e199-207.
Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125(2):e199-207.
Boom, J. A., Tate, J. E., Sahni, L. C., Rench, M. A., Hull, J. J., Gentsch, J. R., Patel, M. M., Baker, C. J., & Parashar, U. D. (2010). Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics, 125(2), e199-207. https://doi.org/10.1542/peds.2009-1021
Boom JA, et al. Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States. Pediatrics. 2010;125(2):e199-207. PubMed PMID: 20083525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. AU - Boom,Julie A, AU - Tate,Jacqueline E, AU - Sahni,Leila C, AU - Rench,Marcia A, AU - Hull,Jennifer J, AU - Gentsch,Jon R, AU - Patel,Manish M, AU - Baker,Carol J, AU - Parashar,Umesh D, Y1 - 2010/01/18/ PY - 2010/1/20/entrez PY - 2010/1/20/pubmed PY - 2010/3/5/medline SP - e199 EP - 207 JF - Pediatrics JO - Pediatrics VL - 125 IS - 2 N2 - OBJECTIVE: The goal was to assess the effectiveness of complete (3-dose) or partial (1- or 2-dose) immunization with pentavalent rotavirus vaccine (RV5) against rotavirus acute gastroenteritis (AGE) in US clinical practice. METHODS: A case-control evaluation was conducted in February through June 2008 at an emergency department in Houston, Texas. Case patients with rotavirus AGE (N = 90) were identified through testing for rotavirus in fecal specimens obtained from 205 children 15 days through 23 months of age presenting with AGE. Control groups included rotavirus-negative AGE patients (N = 115), concurrently enrolled patients with acute respiratory infection (ARI) (N = 228), and up to 10 age- and zip code-matched children sampled from the Houston-Harris County Immunization Registry (HHCIR) for each case patient >8 months of age. Immunization data were obtained from parent records, health care providers, and/or the HHCIR. Vaccine effectiveness was calculated as 1 minus odds of RV5 vaccination for case patients versus control patients, after adjustment for age at presentation and birth date. RESULTS: The vaccine effectiveness of a complete RV5 series was 89% (95% confidence interval [CI]: 70%-96%) and 85% (95% CI: 55%-95%) with rotavirus-negative AGE and ARI control patients, respectively. Immunization data were available for 44% of case patients (n = 40) from the HHCIR; the estimated 3-dose vaccine effectiveness with these HHCIR control patients was 82% (95% CI: 19%-96%). A complete RV5 series conferred 100% protection (95% CI: 71%-100%) against severe rotavirus disease requiring hospitalization and 96% protection (95% CI: 72%-99%) against disease requiring intravenous hydration. Vaccine effectiveness of 1 and 2 doses against hospitalization and emergency department visits was 69% (95% CI: 13%-89%) and 81% (95% CI: 13%-96%), respectively, using rotavirus-negative AGE and ARI control groups combined. CONCLUSIONS: In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE. Partial immunization also conferred substantial protection. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/20083525/Effectiveness_of_pentavalent_rotavirus_vaccine_in_a_large_urban_population_in_the_United_States_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=20083525 DB - PRIME DP - Unbound Medicine ER -